HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sean John appointment

This article was originally published in The Rose Sheet

Executive Summary

Desiree Reid to VP and general manager of Sean John toiletries division, Estee Lauder announces. Exec will lead development and marketing of fragrance products under the Sean John line, expected to debut in fall 2005 under a licensing agreement with Lauder (1"The Rose Sheet" May 24, 2004, p. 7). Reid previously was general manager and VP of marketing at IMAN Cosmetics, where she developed and launched skin care and color cosmetics and spearheaded international expansion of the brand. Exec will report to Estee Lauder Global Brand President John Demsey...

You may also be interested in...



Sean John Fragrances Will Debut Under Lauder License

Estee Lauder is aiming to launch a line of Sean John fragrances in fall 2005, the firm said. The company announced it had signed a licensing agreement with Sean John founder Sean "P. Diddy" Combs May 21

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel